$5.49
3.85% today
Nasdaq, Sep 16, 08:19 pm CET
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Nkarta Inc Stock price

$5.71
+0.74 14.89% 1M
-7.19 55.74% 6M
-0.89 13.48% YTD
+4.08 250.31% 1Y
-21.76 79.21% 3Y
-42.19 88.08% 5Y
-42.19 88.08% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.12 2.15%
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Key metrics

Market capitalization $402.89m
Enterprise Value $163.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.89
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-123.96m
Free Cash Flow (TTM) Free Cash Flow $-109.55m
Cash position $324.82m
EPS (TTM) EPS $-2.01
P/E forward negative
Short interest 15.69%
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Nkarta Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Nkarta Inc forecast:

Buy
100%

Financial data from Nkarta Inc

Jun '24
+/-
%
Net Profit -108 -108
14% 14%
-
Depreciation and Amortization 9.30 9.30
54% 54%
-
Stock Compensation 17 17
9% 9%
-
Operating Cash Flow -94 -94
45% 45%
-
Investments 16 16
73% 73%
-
Dividend Paid - -
-
-
Free Cash Flow -110 -110
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
13 days ago
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Neutral
Seeking Alpha
about one month ago
Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell bur...
Positive
The Motley Fool
about one month ago
Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 150
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today